Zhejiang Huahai Pharmaceutical's subsidiary received a refund of $14.2296 million in U.S. tariffs.

date
19:15 08/07/2026
avatar
GMT Eight
Huahai Pharmaceutical (600521.SH) announced that in February 2026, the Supreme Court of the United States ruled that the government's imposition of tariffs under the International Emergency Economic Powers Act (IEEPA) exceeded its legal authority. As a result, the relevant tariff measures are invalid from the beginning, and the tariffs collected should be refunded to importers. The U.S. Customs and Border Protection (CBP) officially started the refund process on April 20, 2026. As of now, the company's subsidiary Shouke Health has received a total of $14.2296 million in tariff refunds, accounting for 36.36% of the company's net profit attributable to shareholders of the listed company in the most recent audited period.
Zhejiang Huahai Pharmaceutical (600521.SH) announced that in February 2026, the Supreme Court of the United States ruled that the government's imposition of tariffs under the International Emergency Economic Powers Act (IEEPA) exceeded its statutory authority. Therefore, the relevant tariff measures are invalid from the beginning, and the tariffs already collected must be refunded to importers. The U.S. Customs and Border Protection (CBP) officially began the refund process on April 20, 2026. As of now, the company's subsidiary, Shouke Health, has received a total of $14.2296 million in tariff refunds, accounting for 36.36% of the company's recent audited net profit attributable to shareholders of listed companies.